ABN: 89 609 406 911



3 July 2024

Melodiol Q2 Revenue and Updates

Highlights:

- Q2 2024 unaudited revenues total \$4.8m, a 9% increase on Q1 2024 (\$4.4m)
- Brings H1 2024 unaudited revenues to \$9.2m, a 31% increase on H1 2023 (\$7.0m)
- Growth underpinned by strong results at Mernova

Melodiol Global Health Limited (ASX:ME1) ('Melodiol' or 'the Company') is pleased to advise that it has delivered another strong revenue quarter. During Q2 of 2024, Melodiol generated unaudited revenue of \$4.8m, a 9% increase on Q1 2024 (\$4.4m). H2 2024 unaudited revenues now total \$9.2m, a 31% increase on H1 2023 (\$7.0m).

Growth was underpinned by strong results at Mernova. During Q2 of 2024, Mernova had confirmed unaudited purchase orders of \$2.0m (C\$1.8m). This figure is a 25% increase on Q1 2024 (\$1.6m) and a 33% increase on Q2 2023 (\$1.5m). In addition to these strong results, Mernova already has confirmed purchase orders for Q3 2024 of \$452k (C\$411k), providing a strong foundation for the quarter.

Additionally, Mernova achieved a variety of key objectives, including the introduction of a new product category (edibles), the approval of numerous new SKUs in existing provinces, the introduction of new vaporiser flavours and a supply agreement to source additional capacity to keep up with strong demand.

In addition to these strong results, Mernova already has confirmed purchase orders for Q3 2024 of \$452k (C\$411k), providing a strong foundation for the quarter.

During Q2 of 2024, HHI also provided \$2.8m in sales between its Australian and UK divisions. As stated previously, the Company is committed to rationalising non-core business units, while focusing on its core divisions, Mernova and HHI in an effort to achieve profitability as quickly as possible.

Management commentary:

CEO and Managing Director, Mr William Lay said: "We are very pleased to demonstrate quarter on quarter growth for Melodiol as a group. During the last year, the Company has completed a step change in terms of revenue size, and we are sharply focused on Mernova and HHI as our core business units. By focusing on these business units, and rationalising non-core business units, all of our teams are working hard to achieve group profitability as quickly as possible."

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the CEO and MD of Melodiol Global Health Limited.

For further information, please contact:

Investor Enquiries

Melodiol Global Health Limited E: <u>info@cresopharma.com</u> P: +61 (0) 497 571 532

About Melodiol

ABN: 89 609 406 911



Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: https://melodiolglobalhealth.com/

Melodiol offices:

Australia: Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Canada: 59 Payzant Drive, Windsor, Nova Scotia, BON 2TO and 50 Ivey Ln, Windsor, Nova Scotia, BON 2TO

Forward Looking statements

This announcement contains forward-looking statements with respect to Melodiol and its respective operations, strategy, investments, financial performance and condition.

These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Melodiol could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Melodiol and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Melodiol has no obligation to up-date such statements, except to the extent required by applicable laws.